Premium
Lack of effect of glibenclamide on insulin requirements and diabetic control in persons with insulin‐dependent diabetes
Author(s) -
Stocks Alan E.,
Ma Alan,
Howlett Vicki,
Howlett Vicki,
Cameron Donald P.
Publication year - 1988
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1988.tb120732.x
Subject(s) - glibenclamide , insulin , diabetes mellitus , medicine , endocrinology , placebo , glucagon , alternative medicine , pathology
The addition of the sulphonylurea agent, glibenclamide, to the insulin therapy of six patients with insulin‐dependent diabetes mellitus was studied in a double‐blind cross‐over trial. The subjects produced no measurable plasma C‐peptide after stimulation with glucagon, weighed within 10% of their ideal body weight and required approximately 1 U/kg per day of insulin. After one month of close supervision while the patients were being managed with diet and insulin therapy alone, glibenclamide, three times a day, or a placebo, was added to the therapy for one month. After a further one‐month control period, the alternate agent was administered for one month. No change in the insulin requirement or the glycosylated haemoglobin levels, or in the 24‐hour profiles of the plasma glucose and free insulin levels in response to a standard diet, was observed at the end of each treatment period. This study suggests that any enhancement of insulin sensitivity by sulphonylurea treatment in persons with insulin‐dependent diabetes mellitus is only minor and clinically‐unimportant.